Helen Piwnica-Worms, Ph.D.
Department of Experimental Radiation Oncology, Division of Radiation Oncology
About Dr. Piwnica-Worms
Dr. Piwnica-Worms serves as Vice Provost of Science and Professor of Experimental Radiation Oncology. Dr. Piwnica-Worms completed a B.A. in Biology at St. Olaf College (1979), a Ph.D. degree in microbiology and immunology at Duke University Medical School (1984) and a postdoctoral fellowship in pathology at the Dana-Farber Cancer Institute (1988). She was Instructor of Pathology at Harvard Medical School and Dana-Farber Cancer Institute from 1988-1989 prior to moving to Tufts University Medical School where she was Assistant Professor of Physiology (1989-1992) followed by Harvard Medical School and Beth Israel Hospital, Boston where she was Associate Professor of Microbiology and Molecular Genetics (1992-1994). In 1994, Dr. Piwnica-Worms moved to Washington University School of Medicine in St. Louis where she was the Gerty T. Cori Professor and Chair of Cell Biology and Physiology and Professor of Internal Medicine. She also served as Associate Director of Basic Science at the Alvin J. Siteman Cancer Center and co-directed the BRIGHT Institute at Washington University.
Present Title & Affiliation
Primary Appointment
Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Senator A.M. Aikin Jr. Distinguished Chair, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
The goals of my research program are aimed at understanding the function and regulation of proteins involved in cell cycle and checkpoint control; identifying mutations and epigenetic modifications with functional significance to the development and progression of invasive triple negative breast cancer (TNBC); developing and exploiting models that enable cell cycle regulatory proteins, cancer drivers and therapeutic targets to be functionally studied in vertebrate animals and translating results from basic, omic and preclinical studies into improved clinical interventions for breast cancer patients. Recognizing that a key challenge facing breast cancer researchers today is the lack of good preclinical models for studying human breast cancer, we are working with primary human breast tumors obtained directly from patients with TNBC. These tumors are being propagated in the humanized mammary fat pads of immune compromised mice for our discovery, omic and preclinical studies. Many of these human tumors metastasize out of the mammary gland to lung, bone, liver and brain facilitating our studies aimed at identifying drivers of breast cancer metastasis. In addition, we are identifying, characterizing and targeting tumor cells in treatment naïve TNBC that are resistant to front line chemotherapy.
Education & Training
Degree-Granting Education
| 1984 | Duke University, Durham, NC, USA, PHD, Microbiology and Immunology, Laboratory of Jack D. Keene |
| 1979 | St. Olaf College, Northfield, MN, USA, BA, Biology |
Postgraduate Training
| 1984-1988 | Research Fellowship, Postdoctoral Research Fellow in Pathology, Laboratory of Thomas M. Roberts, Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA |
Selected Publications
Peer-Reviewed Articles
- Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H, Cancer Genome Atlas Research Network, Piwnica-Worms H, Ma L, Liang H. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Rep 23(1):213-226.e3, 2018. PMID: 29617661.
- Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN. CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res 78(3):781-797, 2018. e-Pub 2017. PMID: 29229598.
- Powell E, Shao J, Picon HM, Bristow C, Ge Z, Peoples M, Robinson F, Jeter-Jones SL, Schlosberg C, Grzeskowiak CL, Yang F, Wu Y, Wistuba I, Moulder SL, Symmans WF, Scott KL, Edwards JR, Liang H, Heffernan TP, Piwnica-Worms H. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. NPJ Breast Cancer 4:9, 2018. e-Pub 2018. PMID: 29736411.
- Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res 77(14):3870-3884, 2017. e-Pub 2017. PMID: 28490518.
- Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3:49, 2017. e-Pub 2017. PMID: 29238749.
- Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev 35(4):547-573, 2016. PMID: 28025748.
- Powell E, Shao J, Yuan Y, Chen HC, Cai S, Echeverria GV, Mistry N, Decker KF, Schlosberg C, Do KA, Edwards JR, Liang H, Piwnica-Worms D, Piwnica-Worms H. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res 18(1):13, 2016. e-Pub 2016. PMID: 26818199.
- Tinkum KL, Stemler KM, White LS, Loza AJ, Jeter-Jones S, Michalski BM, Kuzmicki C, Pless R, Stappenbeck TS, Piwnica-Worms D, Piwnica-Worms H. Fasting protects mice from lethal DNA damage by promoting small intestinal epithelial stem cell survival. Proc Natl Acad Sci U S A 112(51):E7148-54, 2015. e-Pub 2015. PMID: 26644583.
- Cheruiyot A, Paudyal SC, Kim IK, Sparks M, Ellenberger T, Piwnica-Worms H, You Z. Poly(ADP-ribose)-binding promotes Exo1 damage recruitment and suppresses its nuclease activities. DNA Repair (Amst) 35:106-15, 2015. e-Pub 2015. PMID: 26519824.
- Teasley DC, Parajuli S, Nguyen M, Moore HR, Alspach E, Lock YJ, Honaker Y, Saharia A, Piwnica-Worms, Stewart SA. Flap Endonuclease 1 Limits Telomere Fragility on the Leading Strand. J Biol Chem 290(24):15133-45, 2015. e-Pub 2015. PMID: 25922071.
- Sun L, Miyoshi H, Origanti S, Nice TJ, Barger AC, Manieri NA, Fogel LA, French AR, Piwnica-Worms D, Piwnica-Worms H, Virgin HW, Lenschow DJ, Stappenbeck TS. Type I Interferons Link Viral Infection to Enhanced Epithelial Turnover and Repair. Cell Host Microbe 17(1):85-97, 2015. e-Pub 2014. PMID: 25482432.
- Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov 4(4):405-14, 2014. e-Pub 2014. PMID: 24658082.
- Lewandowski KT, Piwnica-Worms H. Phosphorylation of the E3 ubiquitin ligase RNF41 by the kinase Par-1b is required for epithelial cell polarity. J Cell Sci 127(Pt 2)(Pt 2):315-27, 2014. e-Pub 2013. PMID: 24259665.
- Tinkum KL, White LS, Marpegan L, Herzog E, Piwnica-Worms H. Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice. J Biol Chem 288(39):27999-8008, 2013. e-Pub 2013. PMID: 23918930.
- Huh J, Piwnica-Worms H. CRL4(CDT2) targets CHK1 for PCNA-independent destruction. Mol Cell Biol 33(2):213-26, 2013. e-Pub 2012. PMID: 23109433.
- Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 32(5):577-88, 2013. e-Pub 2012. PMID: 22430210.
- Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 137(2):483-92, 2013. e-Pub 2012. PMID: 23242585.
- Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwnica-Worms H, Caplen NJ, Hollingshead MG, Green JE.. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast Cancer Res 4:R109, 2012. e-Pub 2012. PMID: 22812567.
- Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353-60, 2012. e-Pub 2012. PMID: 22722193.
- Duxin JP, Moore HR, Sidorova J, Karanja K, Honaker Y, Dao B, Piwnica-Worms H, Campbell JL, Monnat RJ, Stewart SA. Okazaki fragment processing-independent role for human Dna2 enzyme during DNA replication. J Biol Chem 287(26):21980-91, 2012. e-Pub 2012. PMID: 22570476.
- Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 122(4):1541-52, 2012. e-Pub 2012. PMID: 22446188.
- Tinkum KL, Marpegan L, White LS, Sun J, Herzog ED, Piwnica-Worms D, Piwnica-Worms H. Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells. Mol Cell Biol 31(18):3759-72, 2011. e-Pub 2011. PMID: 21791610.
- Wang YV, Leblanc M, Fox N, Mao JH, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, Kaushansky K, Wahl GM. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev 25(13):1426-38, 2011. PMID: 21724834.
- Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 67(6):1225-37, 2011. e-Pub 2010. PMID: 20694727.
- Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 17(2):88-96, 2011. e-Pub 2010. PMID: 21087899.
- Lee G, Origanti S, White LS, Sun J, Stappenbeck TS, Piwnica-Worms H. Contributions made by CDC25 phosphatases to proliferation of intestinal epithelial stem and progenitor cells. PLoS One 6(1):e15561, 2011. e-Pub 2011. PMID: 21283624.
- Lennerz JK, Hurov JB, White LS, Lewandowski KT, Prior JL, Planer GJ, Gereau RW, Piwnica-Worms D, Schmidt RE, Piwnica-Worms H. Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. Mol Cell Biol 30(21):5043-56, 2010. e-Pub 2010. PMID: 20733003.
- Honaker Y, Piwnica-Worms H. Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction. Oncogene 29(23):3324-34, 2010. e-Pub 2010. PMID: 20348946.
- Qian Z, Leung-Pineda V, Xuan B, Piwnica-Worms H, Yu D. Human cytomegalovirus protein pUL117 targets the mini-chromosome maintenance complex and suppresses cellular DNA synthesis. PLoS Pathog 6(3):e1000814, 2010. e-Pub 2010. PMID: 20333247.
- Granot Z, Swisa A, Magenheim J, Stolovich-Rain M, Fujimoto W, Manduchi E, Miki T, Lennerz JK, Stoeckert CJ, Meyuhas O, Seino S, Permutt MA, Piwnica-Worms H, Bardeesy N, Dor Y. LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab 10(4):296-308, 2009. PMID: 19808022.
- Lin J, Hou KK, Piwnica-Worms H, Shaw AS. The polarity protein Par1b/EMK/MARK2 regulates T cell receptor-induced microtubule-organizing center polarization. J Immunol 183(2):1215-21, 2009. e-Pub 2009. PMID: 19553522.
- Lee G, White LS, Hurov KE, Stappenbeck TS, Piwnica-Worms H. Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion. Proc Natl Acad Sci U S A 106(12):4701-6, 2009. e-Pub 2009. PMID: 19273838.
- Leung-Pineda V, Huh J, Piwnica-Worms H. DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res 69(6):2630-7, 2009. e-Pub 2009. PMID: 19276361.
- Watkins JL, Lewandowski KT, Meek SE, Storz P, Toker A, Piwnica-Worms H. Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association. Proc Natl Acad Sci U S A 105(47):18378-83, 2008. e-Pub 2008. PMID: 19011111.
- Lovly CM, Yan L, Ryan CE, Takada S, Piwnica-Worms H. Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol Cell Biol 28(19):5874-85, 2008. e-Pub 2008. PMID: 18644861.
- Nakajima H, Yonemura S, Murata M, Nakamura N, Piwnica-Worms H, Nishida E. Myt1 protein kinase is essential for Golgi and ER assembly during mitotic exit. J Cell Biol 181(1):89-103, 2008. e-Pub 2008. PMID: 18378775.
- Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, Piwnica-Worms H. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13(1):36-47, 2008. PMID: 18167338.
- Hurov J, Piwnica-Worms H. The Par-1/MARK family of protein kinases: from polarity to metabolism. Cell Cycle 6(16):1966-9, 2007. e-Pub 2007. PMID: 17721078.
- Tarakanova VL, Leung-Pineda V, Hwang S, Yang CW, Matatall K, Basson M, Sun R, Piwnica-Worms H, Sleckman BP, Virgin HW. Gamma-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication. Cell Host Microbe 1(4):275-86, 2007. PMID: 18005708.
- Hurov JB, Huang M, White LS, Lennerz J, Choi CS, Cho YR, Kim HJ, Prior JL, Piwnica-Worms D, Cantley LC, Kim JK, Shulman GI, Piwnica-Worms H. Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo. Proc Natl Acad Sci U S A 104(13):5680-5, 2007. e-Pub 2007. PMID: 17372192.
- King JB, Gross J, Lovly CM, Piwnica-Worms H, Townsend RR. Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom 21(21):3443-51, 2007. PMID: 17918214.
- Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 26(20):7529-38, 2006. e-Pub 2006. PMID: 17015476.
- Dequiedt F, Martin M, Von Blume J, Vertommen D, Lecomte E, Mari N, Heinen MF, Bachmann M, Twizere JC, Huang MC, Rider MH, Piwnica-Worms H, Seufferlein T, Kettmann R. New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and activity of class IIa histone deacetylases. Mol Cell Biol 26(19):7086-102, 2006. PMID: 16980613.
- Chen YM, Wang QJ, Hu HS, Yu PC, Zhu J, Drewes G, Piwnica-Worms H, Luo ZG. Microtubule affinity-regulating kinase 2 functions downstream of the PAR-3/PAR-6/atypical PKC complex in regulating hippocampal neuronal polarity. Proc Natl Acad Sci U S A 103(22):8534-9, 2006. e-Pub 2006. PMID: 16717194.
- King JB, Gross J, Lovly CM, Rohrs H, Piwnica-Worms H, Townsend RR. Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal Chem 78(7):2171-81, 2006. PMID: 16579595.
- Ferguson AM, White LS, Donovan PJ, Piwnica-Worms H. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol Cell Biol 25(7):2853-60, 2005. PMID: 15767688.
- Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, Piwnica-Worms H, Hibshoosh H, Parsons R. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7(2):193-204, 2005. PMID: 15710331.
- Luker KE, Smith MC, Luker GD, Gammon ST, Piwnica-Worms H, Piwnica-Worms D. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci U S A 101(33):12288-93, 2004. e-Pub 2004. PMID: 15284440.
- Meek SE, Lane WS, Piwnica-Worms H. Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins. J Biol Chem 279(31):32046-54, 2004. e-Pub 2004. PMID: 15161933.
- Hurov JB, Watkins JL, Piwnica-Worms H. Atypical PKC phosphorylates PAR-1 kinases to regulate localization and activity. Curr Biol 14(8):736-41, 2004. PMID: 15084291.
- Chen MS, Ryan CE, Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol 23(21):7488-97, 2003. PMID: 14559997.
- Neely KE, Piwnica-Worms H. Cdc25A regulation: to destroy or not to destroy--is that the only question?. Cell Cycle 2(5):455-7, 2003. PMID: 12963843.
- Schwarz JK, Lovly CM, Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol Cancer Res 1(8):598-609, 2003. PMID: 12805407.
- Bulavin DV, Higashimoto Y, Demidenko ZN, Meek S, Graves P, Phillips C, Zhao H, Moody SA, Appella E, Piwnica-Worms H, Fornace AJ. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 5(6):545-51, 2003. PMID: 12766774.
- Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 99(23):14795-800, 2002. e-Pub 2002. PMID: 12399544.
- Luker GD, Sharma V, Pica CM, Dahlheimer JL, Li W, Ochesky J, Ryan CE, Piwnica-Worms H, Piwnica-Worms D. Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A 99(10):6961-6, 2002. e-Pub 2002. PMID: 11997447.
- Chen F, Zhang Z, Bower J, Lu Y, Leonard SS, Ding M, Castranova V, Piwnica-Worms H, Shi X. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 99(4):1990-5, 2002. e-Pub 2002. PMID: 11842186.
- Rothblum-Oviatt CJ, Ryan CE, Piwnica-Worms H. 14-3-3 binding regulates catalytic activity of human Wee1 kinase. Cell Growth Differ 12(12):581-9, 2001. PMID: 11751453.
- Müller J, Ory S, Copeland T, Piwnica-Worms H, Morrison DK. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell 8(5):983-93, 2001. PMID: 11741534.
- Deming PB, Cistulli CA, Zhao H, Graves PR, Piwnica-Worms H, Paules RS, Downes CS, Kaufmann WK. The human decatenation checkpoint. Proc Natl Acad Sci U S A 98(21):12044-9, 2001. e-Pub 2001. PMID: 11593014.
- Crawford DF, Piwnica-Worms H. The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators. J Biol Chem 276(40):37166-77, 2001. e-Pub 2001. PMID: 11483598.
- Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21(13):4129-39, 2001. PMID: 11390642.
- Chen MS, Hurov J, White LS, Woodford-Thomas T, Piwnica-Worms H. Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol Cell Biol 21(12):3853-61, 2001. PMID: 11359894.
- Hurov JB, Stappenbeck TS, Zmasek CM, White LS, Ranganath SH, Russell JH, Chan AC, Murphy KM, Piwnica-Worms H. Immune system dysfunction and autoimmune disease in mice lacking Emk (Par-1) protein kinase. Mol Cell Biol 21(9):3206-19, 2001. PMID: 11287624.
- Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 20(15):1839-51, 2001. PMID: 11313932.
- Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 60(21):5934-6, 2000. PMID: 11085506.
- Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275(8):5600-5, 2000. PMID: 10681541.
- Parker LL, Sylvestre PJ, Byrnes MJ, Liu F, Piwnica-Worms H. Identification of a 95-kDa WEE1-like tyrosine kinase in HeLa cells. Proc Natl Acad Sci U S A 92(21):9638-42, 1995. PMID: 7568188.
- Diamond MI, Cai S, Boudreau A, Carey CJ, Lyle N, Pappu RV, Swamidass SJ, Bissell M, Piwnica-Worms H, Shao J. Subcellular Localization and Ser-137 Phosphorylation Regulate Tumor-Suppressive Activity of Profilin-1. J Biol Chem. e-Pub 2015. PMID: 25681442.
- Chen X, Kim IK, Honaker Y, Paudyal SC, Koh WK, Sparks M, Li S, Piwnica-Worms H, Ellenberger T, You Z. 14-3-3 Proteins Restrain the Exo1 Nuclease to Prevent Over-resection. J Biol Chem. e-Pub 2015. PMID: 25833945.
- Werden SJ, Sphyris N, Sarkar TR, Paranjape AN, LaBaff AM, Taube JH, Hollier BG, Ramirez-Peña EQ, Soundararajan R, den Hollander P, Powell E, Echeverria GV, Miura N, Chang JT, Piwnica-Worms H, Rosen JM, Mani SA. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth. Oncogene. e-Pub 2016. PMID: 27292262.
Grant & Contract Support
| Title: | Project 2: Imaging and Characterizing Stress Responses In Vivo with p21 Reporter Mice |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| Title: | Combining Targeting of Chk1 and PARP to Triple Negative Breast Cancer, Investigator-Initiated Research Grant |
| Funding Source: | Susan G. Komen for the Cure |
| Role: | Principal Investigator |
| Title: | Project 1: Determine how neomorphic activities of p53 mutant proteins affect sensitivity to Chk1 inhibition |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| Title: | Inhibition of brain metastasis by blocking MAPK12 driver kinase functions |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Administrative Core: A Randomized Clinical Trial Platform with Translational Studies to Overcome Resistance in Triple Negative Breast Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Principal Investigator |
| Title: | The roles of TRIM24 in breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |